NCT05919212View on ClinicalTrials.gov

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

NARecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

February 1, 2026

Conditions
Metastatic Breast Cancer
Interventions
DIAGNOSTIC_TEST

HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment

We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood

Trial Locations (1)

00168

RECRUITING

Fondazione Policlinico A. Gemelli - IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER